Opus Genetics Inc. was recently featured on Good Morning America for its pioneering work in developing gene therapies targeting inherited retinal diseases (IRDs). The segment highlighted the story of Lindsey Rambo, the second participant in Opus Genetics' ongoing Phase 1/2 clinical trial of their investigational gene therapy OPGx-LCA5. This therapy aims to restore vision in individuals with a rare genetic form of blindness caused by mutations in the LCA5 gene. The therapy works by delivering a functional copy of the defective gene directly to retinal cells, with the goal of restoring the function of light-sensing photoreceptors. The news coverage brings attention to the promising early results and ongoing clinical trials, but no new research data or specific trial outcomes were formally announced or presented at this time.